[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urinary-bladder-overactive\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urinary-bladder-overactive":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,41,70,102,144,169,195,218,247,264,284,314,336],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100541933","nxt-post-market-clinical-follow-up-100541933",false,"NCT06336304","NXT Post-Market Clinical Follow-up","NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation","Inclusion Criteria:\n\n* Patients medically indicated for urodynamic study\n* Patient or legally authorized representative provides written authorization and\u002For consent per institution and geographical requirements\n\nExclusion Criteria:\n\n* Patients or legally authorized representative with cognitive or psychiatric condition that interferes with or precludes direct and accurate communication regarding the study, giving informed consent or ability to complete the patient questionnaire\n* Patients with confirmed active bladder infections (not including patients with asymptotic bacteria)\n* Pregnant women\n* Patients with recent (less than 2 weeks) pelvic floor surgery\n* Requires use of suprapubic catheter","ALL",{"count":18,"type":19},180,"ESTIMATED","OBSERVATIONAL","NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation to Confirm Ongoing Safety and Performance in Urodynamic Patient Sub-Populations",[23,24,25,26,27],"Urinary Incontinence","Urinary Obstruction","Urinary Bladder, Overactive","Urinary Bladder, Neurogenic","Urinary Incontinence, Urge","RECRUITING","2026-05-13",{"date":31,"type":32},"2026-05-15","ACTUAL",{"date":34,"type":32},"2024-06-18",{"date":36,"type":19},"2027-03",{"name":38,"class":39},"Laborie Medical Technologies Inc.","INDUSTRY",5,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100531531","vitamin-d-treat-to-target-strategy-for-children-with-overactive-bladder-wet-100531531","NCT06201013","Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet","Efficacy, Neural Repair Mechanism, and Health Economics of a Multimodal Treat-to-Target Strategy Incorporating Vitamin D for Pediatric Overactive Bladder-Wet: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Children older than or equal to 5 years of age with a diagnosis of wet OAB (the diagnosis followed the latest guidelines of ICCS) attending the outpatient clinic of the Department of Urology of the Affiliated Children's Hospital of Chongqing Medical University,\n* children with serum vitamin D levels below 35 ng\u002Fml as indicated by the tests conducted by the hospital\n* children whose guardians have given their informed consent, are able to ensure compliance and have signed a paper-based informed consent form.\n\nExclusion Criteria:\n\n* Those with urinary malformations or serious diseases (e.g., hypospadias, cryptorchidism, posterior urethral valvulae, vesicoureteral reflux, neurogenic bladder, urinary tumors, urinary stones, bladder and urethral injuries, etc.)\n* Those with neurological disorders (e.g., epilepsy, spinal cord injuries, spinal dysplasia, spinal embolism syndrome, multiple sclerosis, and autism spectrum disorders, etc.)\n* People with serious heart disease, abnormal liver and kidney function, lung disease, bone deformity, serious digestive tract disease, genetic metabolic disease\n* People with history of gastrointestinal surgery and urological surgery\n* People with dry stools and long-term constipation\n* People who are taking anticonvulsant and antiepileptic drugs, hormones, and anti-tuberculosis drugs\n* People with history of hypercalcemia, hyperphosphatemia with renal rickets\n* People who have had unexplained hematuria and hematuria with renal rickets within the last year\n* People who have been suffering from severe heart disease or chronic diabetes.\n* participation in other clinical studies at the time of consultation or during the follow-up period of other clinical studies\n* unwillingness to participate in this study","5 Years","18 Years",{"count":18,"type":19},"INTERVENTIONAL",[53],"NA","The purpose of this clinical trial is to investigate whether adding high-dose vitamin D (2,400 IU daily) to standard medical treatment (solifenacin combined with behavioral therapy) is more effective than standard treatment alone for children with overactive bladder-wet (OAB-wet).\n\nOAB-wet causes sudden urinary urges and frequent daytime or incontinence, which significantly impacts a child's quality of life and increases the family's caregiving burden. While solifenacin is a standard medication used to calm the bladder, many children do not achieve complete dryness. This study introduces the \"Treat-to-Target\" (T2T) approach, where clinicians and families set personalized \"functional goals\" (such as zero leakage) and monitor progress closely to adjust care.\n\nThe study aims to answer the following questions:\n\nDoes adding vitamin D help more children achieve their goal of \"zero leakage\" compared to standard treatment? Does vitamin D help repair bladder-related nerves, as measured by a specific marker in the urine? Does this combined approach reduce the family's expenses (like laundry costs and diaper use) and improve the child's self-esteem?\n\nParticipants will be randomly assigned to one of two groups for 12 weeks:\n\nIntervention Group: Standard care (solifenacin + behavioral therapy) plus daily vitamin D (2,400 IU).\n\nControl Group: Standard care (solifenacin + behavioral therapy) alone. Researchers will evaluate symptoms, vitamin D levels, and nerve repair markers at 6 and 12 weeks to determine the best treatment strategy for these children.",[25,56,27],"Overactive Bladder",[25,27,58],"Vitamin D","2026-04-14",{"date":61,"type":32},"2026-04-17",{"date":63,"type":19},"2026-04-20",{"date":65,"type":19},"2027-04-15",{"name":67,"class":68},"Children's Hospital of Chongqing Medical University","OTHER",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":51,"phases":80,"briefSummary":81,"conditions":82,"keywords":89,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},"100625621","ambulatory-long-length-urodynamics-evaluation-100625621","NCT07425015","Ambulatory Long Length URodynamics Evaluation","ALLURE","Inclusion Criteria:\n\n1. Male or female patient must be ≥ 22 years of age.\n2. Patient is a candidate for UDS per standard of care.\n3. Patient is able to provide informed consent.\n\nExclusion Criteria:\n\n1. Patient has one or more symptoms indicative of a urinary tract infection (UTI) (i.e., fever, costovertebral angle pain or tenderness, suprapubic tenderness, worsening urinary frequency, worsening urgency, and\u002For dysuria).\n2. Patient has a history of recurrent UTIs (≥ 3 episodes in previous 12 months).\n3. Patient has used antibiotics within the past 7 days from the baseline\u002Fscreening visit.\n4. Patient diagnosed with neurogenic LUTD (i.e., one or more of these conditions: normal-pressure hydrocephalus, cerebral palsy, spinal cord injuries, traumatic brain injury, stroke, Parkinson's disease, multiple sclerosis, meningomyelocele, spina bifida, dementia, Guillain-Barre syndrome, and tumors involving the central nervous systems or spine).\n5. Patient diagnosed with interstitial cystitis (IC), bladder pain syndrome, painful bladder syndrome or any etiology of chronic pelvic pain syndrome (CPPS).\n6. Patient with a urostomy.\n7. Patient with a colostomy.\n8. Patient has an atypical anatomic structural variation or has had a previous surgical intervention that has permanently changed structural anatomy anywhere along their lower urinary tract (urethra, pelvic floor, urethral sphincter, and\u002For bladder wall) that the principal investigator deems might compromise the placement or retention of the Glean sensors during the study (e.g., strictures).\n9. Patient has a Pelvic Organ Prolapse Quantification (POP-Q) of Grade III or higher (i.e., most distal portion of the prolapse protrudes more than 1 centimeter below the hymen).\n10. Patient with any abnormal or concerning rectal conditions such as ongoing anal fissures, rectocele, fistula, active herpes, or active yeast infections.\n11. Patient has a known inability to void.\n12. Patient has a previous history of radiation leading to bleeding (e.g., hemorrhagic radiation cystitis).\n13. Patient is pregnant (as confirmed by urine pregnancy test or medical history) or breastfeeding, pregnant within the past 6 months, or intending to become pregnant during the study period.\n14. Patients who may not be able to independently use a smart device.\n15. Subjects who, at the principal investigator's determination, would not be appropriate for this study.","22 Years",{"count":79,"type":19},101,[53],"A prospective, open-label, single arm interventional trial evaluating the safety and performance of the in-clinic and extended monitoring of the lower urinary tract using the Glean Urodynamics System.",[83,25,84,85,86,87,88],"Urology","Benign Prostatic Hyperplasia","Urodynamics","Home Monitoring","Urinary Incontinence (UI)","Lower Urinary Tract Dysfunction",[90,91,92],"Bright Uro","Glean Urodynamics System","Uroflowmetry","2026-04-13",{"date":95,"type":32},"2026-04-15",{"date":97,"type":32},"2026-02-17",{"date":99,"type":19},"2027-06",{"name":90,"class":39},7,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":109,"minAge":49,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":51,"phases":112,"briefSummary":114,"conditions":115,"keywords":121,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":143},"100622722","phase-4-a-randomized-placebo-controlled-trial-of-nitrous-oxide-during-in-office-bladder-botox-injections-100622722","NCT07387315","A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections","A Randomized, Placebo Controlled Trial of Nitrous Oxide\u002FOxygen Plus Standard Care Versus Standard Care Alone During In-office Intradetrusor onabotulinumtoxinA (Botox) Injections","Inclusion Criteria:\n\n* Adult women ≥18 years old scheduled for in-office intradetrusor botulinum toxin injection and able to consent.\n\nExclusion Criteria:\n\n* Known\u002Fsuspected vitamin B12 or folate deficiency or high-risk state (e.g., pernicious anemia, malabsorption, post-bariatric or strict vegan without supplementation)\n* currently pregnant\n* severe\u002Funstable pulmonary disease or baseline hypoxemia requiring supplemental home oxygen\n* eye or ear surgery in the last six weeks\n* trapped-air conditions (e.g., untreated pneumothorax, bowel obstruction)\n* severe active otitis\u002Fsinus disease\n* inability to follow directions\n* history of adverse reaction to nitrous oxide","FEMALE",{"count":111,"type":19},96,[113],"PHASE4","The goal of this clinical trial is to assess if a mix of nitrous oxide and oxygen can improve pain control during bladder Botox injections. The primary question it aims to answer is: Does using nitrous oxide lower the overall level of pain during the procedure?\n\nResearchers will compare a 50:50 nitrous oxide\u002Foxygen mixture (administered with the Pro-Nox system) plus standard care (with lidocaine in the bladder) to sham mask plus standard care to see if nitrous oxide works better for lowering pain.\n\nParticipants will:\n\n* Receive their bladder Botox injection in the office setting\n* Either use nitrous oxide\u002Foxygen plus standard care during the procedure, or sham mask plus standard care\n* Answer brief questions about pain, anxiety, satisfaction, and willingness to repeat the procedure",[56,116,117,118,23,25,26,119,27,120],"Neurogenic Bladder","Urge Incontinence","Pain","Urinary Bladder Neurogenesis","Pelvic Floor Disorders",[56,23,117,122,123,124,125,126,127,128,129,130,131,132],"Intradetrusor Injection","OnabotulinumtoxinA","Botox","Bladder Botox","Botulinum Toxins, Type A","Pain Management","Analgesia","Nitrous Oxide","Office-based Procedures","Urogynecology","Pelvic Floor Disorder","NOT_YET_RECRUITING","2026-01-28",{"date":136,"type":32},"2026-02-04",{"date":138,"type":19},"2026-02",{"date":140,"type":19},"2026-12",{"name":142,"class":68},"TriHealth Inc.",2,{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":109,"minAge":49,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":51,"phases":152,"briefSummary":153,"conditions":154,"keywords":155,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":69},"100621153","comparison-of-the-efficacy-of-perineal-and-intravaginal-electrical-stimulation-in-women-with-idiopathic-overactive-bladder-100621153","NCT07366918","Comparison of the Efficacy of Perineal and Intravaginal Electrical Stimulation in Women With Idiopathic Overactive Bladder","Inclusion Criteria:\n\n* Women over the age of 18 with a clinical diagnosis of idiopathic OAB\n* Intolerant or unresponsive to antimuscarinic or oral β3 adrenoceptor agonist (mirabegron) medications and not using them for at least 4 weeks\n* Ability to understand the procedures, advantages, and potential side effects\n* Ability to provide written, informed consent\n* Pelvic floor muscle (PFM) strength of 3\u002F5 or higher (modified Oxford scale, minimum: 0 - maximum: 5)\n\nExclusion Criteria:\n\n* Women with pure stress urinary incontinence\n* History of conservative treatment for OAB within the last 6 months (MI, IVES, perineal ES, etc.)\n* Pregnant or planning to become pregnant at the time of the study\n* Diagnosis of vaginal infection, urinary tract infection, or cancer\n* Women with urinary incontinence within the last 3 months Those who have undergone urogynecological surgery\n* Those with genital area disorders that may preclude the use of a vaginal probe or perineal electrode\n* Those diagnosed with stage 2 or higher according to the Pelvic Organ Prolapse Assessment (POP-Q)\n* Those with a pacemaker or implanted defibrillator\n* Those with neurogenic bladder or a history of neurological disease\n* Those with a urine residual of more than 100 ml detected by ultrasound (using an ultrasound device)\n* Those with allergies to condoms or lubricating gels used with a vaginal probe or perineometer",{"count":151,"type":19},63,[53],"The investigators conducted a prospective, randomized double-blind, placebo-controlled study based on a placebo technique to evaluate the efficacy of IVES vs perineal ES in women with idiopathic OAB.\n\nThe main questions aimed to be answered are:\n\nIs Intravaginal Electrical Stimulation (IVES) or perineal ES more effective on clinical parameters related to incontinence and quality of life in women with idiopathic overactive bladder (OAB)? Participants (n:63) with idiopathic OAB who meet the exclusion and inclusion criteria will be divided into 3 groups using a randomization table. The first group will receive IVES and bladder training (n:21), second group will receive perineal ES and bladder training (n:21) and third group will receive bladder training (n=21) . Measurements will be performed twice in total, before and at the end of treatment (8th week).",[25],[156,157,158,159],"Idiopathic overactive bladder","Urinary incontinence","perineal electrical stimulation","Intravaginal electrical stimulation","2026-01-16",{"date":162,"type":32},"2026-01-26",{"date":164,"type":32},"2025-12-01",{"date":166,"type":19},"2027-01-01",{"name":168,"class":68},"Pamukkale University",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":51,"phases":179,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":194},"100610415","phase-1-long-term-follow-up-study-of-patients-who-received-eg110a-a-non-replicative-herpes-simplex-virus-1-derived-gene-therapy-100610415","NCT07227285","Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy","Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy Expressing a Transgene Encoding the Light Chain of Botulinum Toxin F","Inclusion Criteria:\n\n\\- All participants who received at least one dose\u002Finjection of EG110A in Study EG110A-001-01 and have prematurely discontinued or completed that study.\n\nExclusion Criteria:\n\n* Participant plans to participate in another investigational gene therapy study\n* Participant has an uncontrolled intercurrent illness, any disorder, or current substance abuse that would limit compliance with study requirements in the opinion of the investigator","75 Years",{"count":178,"type":19},16,[180,181],"PHASE1","PHASE2","The aim of this study is to continue following participants who have received EG110A during five years to know how it is tolerated in humans, any side-effects it may cause and what might be an effective dose over five years. All participants who have received at least one dose\u002Finjection of EG110A in a previous clinical study of EG110A will be asked to roll-over to this long-term follow-up study upon either early discontinuation from, or completion of, that study.",[25,184],"Spinal Cord Injury","2025-11-10",{"date":187,"type":32},"2025-11-12",{"date":189,"type":19},"2026-04",{"date":191,"type":19},"2031-04",{"name":193,"class":39},"EG 427",4,{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":109,"minAge":49,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":51,"phases":204,"briefSummary":206,"conditions":207,"keywords":208,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":69},"100601757","phase-3-the-effect-of-nighttime-mirabegron-solifenacin-tolterodine-or-oxybutynin-on-nocturia-sexual-function-autonomic-function-and-lower-urinary-tract-blood-flow-perfusion-in-women-with-overactive-bladder-syndrome-randomized-controlled-trial-100601757","NCT07114640","The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial","Far Eastern Memorial Hospital","Inclusion Criteria:\n\n* \\>18 years old.\n* female patients with overactive bladder syndrome\n\nExclusion Criteria:\n\n* Clinically significant dysuria (inability to urinate, difficulty urinating).\n* Severe stress urinary incontinence (urinary incontinence caused by coughing).\n* Mixed urinary incontinence mainly caused by stress urinary incontinence (urinary incontinence caused by coughing as the main symptom).\n* Contraindications to antimuscarinic drugs or adrenergic receptor agonists.",{"count":203,"type":19},220,[205],"PHASE3","The optimal medication for women with nocturia remains uncertain. This clinical trial aimed to determine the most effective medication for women with overactive bladder and nocturia. Its primary objectives were to answer the following questions:\n\nWhich medication is most effective for women with nocturia? Which medication has the least effect on heart rate variability in women with nocturia?",[25],[209],"autonomic nerve system, nocturia, psychologic distress, sexual function, bladder blood perfusion, heart rate variability, overactive bladder syndrome","2025-08-04",{"date":212,"type":32},"2025-08-11",{"date":214,"type":19},"2025-08-07",{"date":216,"type":19},"2028-12-31",{"name":200,"class":68},{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":109,"minAge":225,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":51,"phases":229,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":69},"100552948","phase-4-efficacy-of-solifenacin-or-mirabegron-with-local-estrogen-versus-combination-pharmacotherapy-for-overactive-bladder-100552948","NCT06479720","Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder","Efficacy and Safety of Solifenacin or Mirabegron With Local Estrogen Versus Combination Treatment With Mirabegron and Solifenacin for Refractory Overactive Bladder","Inclusion Criteria:\n\n* Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with anti-muscarinics were enrolled for prospective study.\n\nExclusion Criteria:\n\n* Postvoid urine retention before treatment\n* Women who had medical illness and contraindication for using solifenacin and mirabegron, such as narrow-angle glaucoma and hypertension\n* Concerns for using estrogen include: Women with history of cerebrovascular disease; thromboembolic disorders; gallbladder disease; known or suspected breast carcinoma; estrogen-dependent neoplasm or undiagnosed abnormal genital bleeding.","40 Years","90 Years",{"count":228,"type":19},300,[113],"To investigates the effects of solifenacin or mirabegron with local estrogen versus combination treatment with solifenacin and mirabegron in women with overactive bladder",[232,25],"Effect of Drug",[234,235,236,237],"Detrusor overactivity","Combined pharmacotherapy","Estrogens","Effectiveness","2025-05-06",{"date":240,"type":32},"2025-05-09",{"date":242,"type":32},"2022-06-16",{"date":244,"type":19},"2026-12-31",{"name":246,"class":68},"Mackay Memorial Hospital",{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":109,"minAge":225,"maxAge":226,"enrollmentInfo":254,"targetDuration":4,"studyType":51,"phases":256,"briefSummary":257,"conditions":258,"keywords":259,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":260,"startDateStruct":261,"completionDateStruct":262,"leadSponsor":263,"locationsCount":69},"100531246","phase-4-efficacy-of-combined-pharmacotherapy-versus-solifenacin-with-vaginal-estrogen-cream-for-women-with-detrusor-overactivity-100531246","NCT06197295","Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity","Efficacy and Safety of Solifenacin Combined With Mirabegron Versus Solifenacin With Vaginal Estrogen Cream for the Treatment of Detrusor Overactivity","Inclusion Criteria:\n\n* Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with anti-muscarinics were enrolled for prospective study.\n\nExclusion Criteria:\n\n* Postvoid urine retention before treatment\n* Women who had medical illness and contraindication for using solifenacin and mirabegron, such as narrow-angle glaucoma and hypertension\n* Concerns for using estrogen include: Women with history of cerebrovascular disease; thromboembolic disorders; gallbladder disease; known or suspected breast carcinoma; estrogen-dependent neoplasm or undiagnosed abnormal genital bleeding.\n* Women who were on hormone replacement therapy within 3 months were also excluded from the study",{"count":255,"type":19},200,[113],"To investigates the effects of combined pharmacotherapy with solifenacin and mirabegron versus solifenacin with vaginal estrogen cream in women with detrusor overactivity.",[25,232],[234,235,236,237],{"date":240,"type":32},{"date":242,"type":32},{"date":244,"type":19},{"name":246,"class":68},{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":109,"minAge":271,"maxAge":226,"enrollmentInfo":272,"targetDuration":4,"studyType":51,"phases":273,"briefSummary":274,"conditions":275,"keywords":276,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":279,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":283,"locationsCount":69},"100513700","phase-4-evaluation-the-efficacy-between-botox-injection-and-combination-pharmacotherapy-in-patients-with-detrusor-overactivity-100513700","NCT05968885","Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity","Evaluation of the Efficacy and Urodynamic Outcomes Between Intradetrusor onabotulinumtoxinA Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity","Inclusion Criteria:\n\n* Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with either anti-muscarinics or β3-adrenoceptor agonists were enrolled for prospective study\n\nExclusion Criteria:\n\n* Postvoid urine retention before treatment","20 Years",{"count":228,"type":19},[113],"To investigates the effects of botulinum toxin type A bladder injection compared to combined pharmacotherapy with Mirabegron and Solifenacin.",[25,85,232],[234,277,235,278,237],"Urodynamic study","Botulinum Toxins",{"date":240,"type":32},{"date":281,"type":32},"2021-10-01",{"date":244,"type":19},{"name":246,"class":68},{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":292,"sex":109,"minAge":49,"maxAge":293,"enrollmentInfo":294,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":296,"conditions":297,"keywords":301,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":69},"100587824","elastographic-assessment-of-suburethral-tissue-in-continent-and-incontinent-women-100587824","NCT06933407","Elastographic Assessment of Suburethral Tissue in Continent and Incontinent Women","This Study Investigates the Role of Strain Elastography in Assessing Paraurethral Tissue Elasticity in Continent and Incontinent Pre- and Postmenopausal Women. It Also Evaluates the Predictive Value of Strain Elastography Compared to Other Pelvic Imaging Modalities, Including Conventional Ultrasound Examinations, in Supporting Treatment Decision-making for Urinary Incontinence.","SE-inc1","Inclusion Criteria:\n\n* Clinical diagnosis of stress urinary incontinence (SUI) based on patient history, physical examination, and\u002For urodynamic assessment.\n\nExclusion Criteria:\n\n* Pelvic malignancy or history of pelvic radiation therapy\n* Urge urinary incontinence (UUI) or detrusor overactivity\n* Pelvic organ prolapse (POP) stage ≥ II (based on POP-Q classification)\n* Pregnancy or recent postpartum status (less than 6 months postpartum)\n* Neurological disorders affecting bladder function\n* Recurrent urinary tract infections (UTIs) or active lower urinary tract infection\n* Inability to undergo study procedures\n* Cognitive impairment or psychiatric conditions affecting informed consent or compliance",true,"99 Years",{"count":295,"type":19},80,"Strain elastography (SE) will be utilized as a non-invasive imaging technique to evaluate tissue elasticity and biomechanical properties in women with stress urinary incontinence (SUI) and in continent controls. The primary aim is to determine whether SE can detect differences in paraurethral tissue stiffness between these groups. Given the established role of tissue elasticity in the pathophysiology of SUI, SE will be investigated as a potential diagnostic tool in urogynecological evaluations.\n\nThis prospective cohort study will be conducted at a tertiary referral center. All participants will undergo introital two-dimensional (2D) ultrasound in the midsagittal plane at rest. SE will be performed in three predefined suburethral regions of interest (ROIs):\n\n* internal urethral orifice (IUO) level\n* midurethra (MU) level\n* external urethral orifice (EUO) level\n\nThe adipose layer (AL) between the external urethral meatus and the pubic symphysis will serve as the reference tissue, representing the softest anatomical structure in the region.\n\nDescriptive and comparative statistical analyses will be conducted to assess differences in paraurethral tissue stiffness between the study groups.\n\nIt is hypothesized that SE will be able to detect differences in paraurethral tissue elasticity, with SUI being associated with increased tissue compliance. The study also aims to determine whether SE can reliably distinguish between varying degrees of tissue stiffness in women with SUI and continent controls.\n\nPathophysiological focus:\n\nThe study will explore key mechanisms underlying SUI, including:\n\n* Weakened bladder neck support\n* Impaired urethral stabilization due to increased tissue elasticity and collagen degradation\n* While conventional 2D ultrasound provides anatomical information, it does not directly evaluate tissue biomechanics. In contrast, SE enables real-time visualization of tissue elasticity, offering a promising adjunct to traditional urogynecological assessment methods.\n\nStandardization and Protocol\n\nThe study will follow a standardized protocol to ensure reproducibility and high-quality data. Key methodological elements include:\n\n* Minimal probe compression during introital ultrasound to avoid artifacts\n* Bladder emptying prior to examination to eliminate confounding effects\n* Carefully standardized ROI placement across all patients\n* Controlled image acquisition conditions to reduce variability\n\nFuture Directions\n\n* Future research based on this study will aim to:\n* Optimize SE protocols and refine ROI placement strategies\n* Establish clinical cutoff values for differentiating tissue stiffness in SUI vs. continent women\n* Assess the long-term effects of pelvic floor muscle training (PFMT) and vaginal estrogen therapy on paraurethral biomechanics\n* Facilitate the integration of SE into routine urogynecological practice to support early diagnosis and personalized treatment strategies for SUI",[23,298,87,25,299,300],"Urinary Incontinence, Stress","Incontinence, Overactive Bladder, Stress Urinary Incontinence","Stress Urinary Incontinence (SUI)",[23,302,303,304],"Bladder dysfunction","Urine leakage","Stress urinary incontinence (SUI)","2025-04-15",{"date":307,"type":32},"2025-04-18",{"date":309,"type":32},"2024-08-16",{"date":311,"type":19},"2030-01-01",{"name":313,"class":68},"Szeged University",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":109,"minAge":49,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":51,"phases":323,"briefSummary":324,"conditions":325,"keywords":326,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":69},"100546096","transcutaneous-medial-plantar-nerve-stimulation-in-women-with-idiopathic-overactive-bladder-100546096","NCT06390488","Transcutaneous Medial Plantar Nerve Stimulation in Women With Idiopathic Overactive Bladder","Transcutaneous Medial Plantar Nerve Stimulation in Women With Idiopathic Overactive Bladder: A Prospective Randomized Double-blind Placebo Controlled Trial","Inclusion Criteria:\n\n* Women over the age of 18 with clinical diagnosis of idiopathic OAB\n* Not tolerated or unresponsive to antimuscarinics and discontinued at least 4 weeks\n* Able to understand the procedures, advantages and possible side effects\n* Willing and able to complete the voiding diary and QoL questionnaire\n* The strength of pelvic floor muscles 3\u002F5 and more\n\nExclusion Criteria:\n\n* Women with stress urinary incontinence\n* History of conservative therapy (T-MPNS and Transcutaneous Tibial Nerve Stimulation\u002FPTNS) within 6 months\n* Pregnancy or intention to become pregnant during the study\n* Current vulvovaginitis or urinary tract infections or malignancy\n* Anatomic or posttraumatic malformations\u002Fskin disorders of medial plantar nerve region on inner foot that cannot allow to apply the electrodes\n* More than stage 2 according to the pelvic organ prolapse quantification (POP-Q)\n* Cardiac pacemaker, implanted defibrillator\n* Previous urogynecological surgery within 3 months\n* Neurogenic bladder, signs of neurologic abnormalities at objective examination; history of the peripheral or central neurologic pathology\n* Ultrasonographic evidence of post-void residual volume more than 100 ml",{"count":322,"type":19},40,[53],"The investigators conducted a prospective, randomized double-blind, placebo-controlled study based on a placebo technique to evaluate the efficacy of T-MPNS vs placebo in women with idiopathic OAB.\n\nThe main questions aimed to be answered are:\n\nWhat are the effects of Transcutaneous Medial Plantar Nerve Stimulation (T-MPSS) on clinical parameters related to incontinence and quality of life compared to the placebo group in women with idiopathic overactive bladder (OAB)? Participants (n:40) with idiopathic OAB who meet the exclusion and inclusion criteria will be divided into 2 groups using a randomization table. The first group will receive T-MPSS (n:20) and the second group will receive placebo T-MPSS (n:20). Measurements will be performed twice in total, before and at the end of treatment (6th week).",[25],[156,327,157],"Transcutaneous medial plantar nerve stimulation","2024-11-27",{"date":330,"type":32},"2024-12-02",{"date":332,"type":19},"2024-11-28",{"date":334,"type":19},"2025-02-28",{"name":168,"class":68},{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":11,"sex":109,"minAge":49,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":51,"phases":345,"briefSummary":346,"conditions":347,"keywords":353,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":143},"100385978","phase-4-post-procedural-pain-associated-with-5-versus-20-intravesical-injections-of-onabotulinumtoxin-a-100385978","NCT04305743","Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A","Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A for Treatment of Overactive Bladder: a Multi-center Randomized Controlled Trial","Inclusion Criteria:\n\n* Women \\>=18 years of age with diagnosis of urinary urgency, urinary frequency, urgency urinary incontinence, overactive bladder.\n* Procedure scheduled in either the outpatient clinic or the operating room to be performed without use of sedation, general, or neuraxial anesthesia.\n\nExclusion Criteria:\n\n* Male gender.\n* Women \\\u003C18 years of age.\n* Non-English speaking.\n* Pregnancy (patient will self-report pregnancy).\n* Participant has symptoms of overactive bladder due to any known neurological reason (e.g. spinal cord injury, multiple sclerosis, cerebrovascular accident, Alzheimer's disease, Parkinson's disease, etc.)\n* Participant uses clean intermittent catheterization or indwelling catheter to manage urinary incontinence.\n* Participant has a history or current diagnosis of bladder cancer or other urothelial malignancy.\n* Participant has a known allergy or sensitivity to any botulinum toxin preparation.\n* Participant has any medical condition that may put her at increased risk with exposure to onabotulinumtoxin A, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis.\n* Participant is scheduled for administration of onabotulinumtoxin A with use of sedation, general, or neuraxial anesthesia.",{"count":344,"type":19},60,[113],"Currently, in clinical practice there has been no standardization in the number of injections a single dose of intradetrusor onabotulinumtoxin A is administered in. Given the increasing use of this treatment modality, the aim of this study is to compare outcomes for patients given a 100 unit dose of onabotulinumtoxin A split into 5 as compared to 20 injections for the treatment of overactive bladder or urgency urinary incontinence refractory to medical treatment.",[25,348,349,350,351,352],"Incontinence, Urge","Incontinence, Urinary","Urinary Urge Incontinence","Urinary Frequency More Than Once at Night","Nocturia",[354,355,356,357,358],"overactive bladder","urgency urinary incontinence","onabotulinumtoxin","bladder","botox","2020-11-03",{"date":361,"type":32},"2020-11-05",{"date":363,"type":32},"2019-10-09",{"date":365,"type":19},"2021-06-01",{"name":367,"class":68},"University of South Florida"]